Christopher Malaisrie S, Chiu Stephen, Schimmel Daniel, Samant Maanasi, Avery Ryan, Rahsepar Amir, Allen Bradley, Raza Yasmin, Freed Benjamin, Mylvaganam Ruben, Cuttica Michael J
Division of Cardiac Surgery, Department of Surgery Northwestern University Feinberg School of Medicine Chicago Illinois.
Division of Cardiology, Department of Medicine Northwestern University Feinberg School of Medicine Chicago Illinois.
Pulm Circ. 2025 Apr 21;15(2):e70085. doi: 10.1002/pul2.70085. eCollection 2025 Apr.
Recent international guidelines recommend a multidisciplinary evaluation and care model for patients with chronic thromboembolic pulmonary hypertension (CTEPH), but there is a paucity of supporting data. The aim of this study was to describe the outcomes of a multidisciplinary team approach to the comprehensive care of CTEPH patients. This single-center cohort study enrolled 166 consecutive adult patients undergoing CTEPH treatment evaluation from 2016 to 2022 at a tertiary care, academic regional referral and comprehensive CTEPH center with pulmonary thromboendarterectomy (PTE) and balloon pulmonary angioplasty (BPA) capabilities. Patients underwent PTE, BPA, or medical management after consensus evaluation by a multidisciplinary team including pulmonary hypertension physicians, surgeons, interventional cardiologists, and radiologists. 86% (142/166) of patients underwent interventional therapies; 100 (60%) underwent PTE and 42 (25%) BPA. Of the 24 (14%) medically treated patients, 13 patients were offered but deferred intervention; 11 patients had non-intervenable disease. 30-day mortality in both PTE and BPA was 0%. 1- and 3-year survival was 99% and 96% for PTE, 100% and 93% for BPA, 79% and 79% for medical management. Patients who underwent PTE had the best hemodynamic response (∆PVR: PTE -278.8 ± 366.9 dyne/sec/cm; BPA -15.9 ± 171.8 dyne/sec/cm; medical -60.2 ± 233.1 dyne/sec/cm; = 0.001), largest improvement in Borg Dyspnea Scale; [PTE -1.0 (-2.8 to 0.0), BPA + 0.5 (-0.8 to 5.0), medical +1.0 (0.75 to 3.0), = 0.01], and most improvement in NYHA functional class [% improving at least 1 functional class: PTE 64% (47/73), BPA 18% (5/28), medical 21% (4/19), = 0.0004].
近期的国际指南推荐对慢性血栓栓塞性肺动脉高压(CTEPH)患者采用多学科评估与治疗模式,但支持数据匮乏。本研究旨在描述多学科团队对CTEPH患者进行综合治疗的效果。这项单中心队列研究纳入了2016年至2022年期间在一家具备肺血栓内膜剥脱术(PTE)和球囊肺动脉成形术(BPA)能力的三级医疗、学术区域转诊及综合性CTEPH中心连续接受CTEPH治疗评估的166例成年患者。患者在由肺动脉高压医生、外科医生、介入心脏病学家和放射科医生组成的多学科团队进行共识评估后,接受了PTE、BPA或药物治疗。86%(142/166)的患者接受了介入治疗;100例(60%)接受了PTE,42例(25%)接受了BPA。在24例(14%)接受药物治疗的患者中,13例患者被建议接受介入治疗但推迟了;11例患者患有无法进行介入治疗的疾病。PTE和BPA的30天死亡率均为0%。PTE的1年和3年生存率分别为99%和96%,BPA分别为100%和93%,药物治疗分别为79%和79%。接受PTE的患者血流动力学反应最佳(肺血管阻力变化:PTE -278.8±366.9达因/秒/平方厘米;BPA -15.9±171.8达因/秒/平方厘米;药物治疗 -60.2±233.1达因/秒/平方厘米;P = 0.001),Borg呼吸困难量表改善最大[PTE -1.0(-2.8至0.0),BPA +0.5(-0.8至5.0),药物治疗 +1.0(0.75至3.0),P = 0.01],纽约心脏协会(NYHA)功能分级改善最明显[至少改善1个功能分级的百分比:PTE 64%(47/73),BPA 18%(5/28),药物治疗21%(4/19),P = 0.0004]。